Boundless Bio annual return on equity
2024
2025
Boundless Bio Return on Equity (ROE) Growth & History (BOLD)
Boundless Bio's return on equity was −46.69% for fiscal 2025.
View full Boundless Bio company overviewBoundless Bio annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −46.69% | +508.18 pp |
| 2024 | 2024-12-31 | −554.86% | — |
Boundless Bio quarterly return on equity
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −31.10% | −19.01 pp |
| Q1 2026 | 2026-03-31 | −14.65% | −3.68 pp |
| Q4 2025 | 2025-12-31 | −12.34% | −1.92 pp |
| Q3 2025 | 2025-09-30 | −11.92% | −2.33 pp |
| Q2 2025 | 2025-06-30 | −12.09% | +77.11 pp |
| Q1 2025 | 2025-03-31 | −10.97% | — |
| Q4 2024 | 2024-12-31 | −10.42% | — |
| Q3 2024 | 2024-09-30 | −9.59% | — |
| Q2 2024 | 2024-06-30 | −89.20% | — |
Boundless Bio return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Boundless Bio's return on equity increased from −554.86% to −46.69%, a change of +508.18 percentage points. The latest reported quarter, Q2 2026, shows −31.10%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Boundless Bio source filings ↗